Evidence map›Paper›PMID 30352784›Full record

Trial reportBlood2018

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Nizar J Bahlis, Heather Sutherland, Darrell White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P Venner, Cristina Gasparetto, Aldo Del Col, Paola Neri and 8 more

Open access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Current Status of Molecularly Targeted Therapeutics in Blood Cancers.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Treatment of multiple myeloma with selinexor: a review.Therapeutic advances in hematology · 2024
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 2 countries.

Nizar J BahlisCharbonneau Cancer Research Institute, Calgary, AB, Canada.
Heather SutherlandVancouver General Hospital, Vancouver, BC, Canada.
Darrell WhiteQEII Health Sciences Center, Dalhousie University, Halifax, NS, Canada.
Michael SebagRoyal Victoria Hospital, Montreal, QC, Canada.
Suzanne LentzschMultiple Myeloma and Amyloidosis Service, Columbia University, New York, NY.
Rami KotbCancer Centre Manitoba, Winnipeg, MB, Canada.
Christopher P VennerCross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Cristina GasparettoDuke University Cancer Center, Durham, NC.
Aldo Del ColMyeloma Canada, Dorval, QC, Canada.
Paola NeriCharbonneau Cancer Research Institute, Calgary, AB, Canada.
Donna ReecePrincess Margaret Cancer Center, Toronto, ON, Canada; and.
Michael KauffmanKaryopharm Therapeutics Inc, Newton, MA.
Sharon ShachamKaryopharm Therapeutics Inc, Newton, MA.
T J UngerKaryopharm Therapeutics Inc, Newton, MA.
Jacqueline JehaKaryopharm Therapeutics Inc, Newton, MA.
Jean-Richard Saint-MartinKaryopharm Therapeutics Inc, Newton, MA.
Jatin ShahKaryopharm Therapeutics Inc, Newton, MA.
Christine ChenPrincess Margaret Cancer Center, Toronto, ON, Canada; and.
Karyopharm Therapeutics (United States) · USPrincess Margaret Cancer Centre · CAAmyloidosis Foundation · USCancerCare Manitoba · CADalhousie University · CADuke University · USRoyal Victoria Hospital · CAUniversity of Alberta · CAVancouver General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors (PI) through suppression of NF-κB signaling and nuclear retention of tumor suppressor proteins. We tested selinexor in combination with low-dose bortezomib and dexamethasone (SVd) for the treatment of relapsed or refractory multiple myeloma (MM). The primary objectives of this study were to determine the safety profile, overall response rate (ORR), and a recommended phase 2 dose (RP2D) of SVd. We enrolled 42 patients to receive selinexor (60, 80, or 100 mg orally) plus bortezomib (1.3 mg/m

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDisease-Free SurvivalFemaleHumansHydrazinesMaleMiddle AgedMultiple MyelomaSurvival RateTriazolesBortezomibDexamethasoneHydrazinesselinexorTriazoles

Identifiers

PMID30352784
PMCPMC6302280
OpenAlexW2897241170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.